nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrexate—stomach cancer—esophageal cancer	0.249	0.57	CtDrD
Methotrexate—lung cancer—esophageal cancer	0.187	0.43	CtDrD
Methotrexate—ABCC2—esophageal cancer	0.137	0.731	CbGaD
Methotrexate—TYMS—Capecitabine—esophageal cancer	0.123	0.559	CbGbCtD
Methotrexate—ABCB1—esophageal cancer	0.0503	0.269	CbGaD
Methotrexate—ABCC3—Cisplatin—esophageal cancer	0.0321	0.146	CbGbCtD
Methotrexate—ABCC2—Carboplatin—esophageal cancer	0.0171	0.0776	CbGbCtD
Methotrexate—ABCG2—Carboplatin—esophageal cancer	0.0154	0.0701	CbGbCtD
Methotrexate—ABCC2—Cisplatin—esophageal cancer	0.0146	0.0663	CbGbCtD
Methotrexate—ABCG2—Cisplatin—esophageal cancer	0.0132	0.0599	CbGbCtD
Methotrexate—ABCB1—Cisplatin—esophageal cancer	0.00475	0.0216	CbGbCtD
Methotrexate—Hepatic fibrosis—Capecitabine—esophageal cancer	0.00298	0.0621	CcSEcCtD
Methotrexate—FOLR1—exocrine gland—esophageal cancer	0.00268	0.0711	CbGeAlD
Methotrexate—Spinal cord disorder—Cisplatin—esophageal cancer	0.00258	0.0538	CcSEcCtD
Methotrexate—Leukoencephalopathy—Cisplatin—esophageal cancer	0.00258	0.0538	CcSEcCtD
Methotrexate—Urine output—Cisplatin—esophageal cancer	0.0014	0.0292	CcSEcCtD
Methotrexate—Gastrointestinal ulcer haemorrhage—Cisplatin—esophageal cancer	0.00127	0.0265	CcSEcCtD
Methotrexate—Nail changes—Capecitabine—esophageal cancer	0.00124	0.0258	CcSEcCtD
Methotrexate—FOLR1—epithelium—esophageal cancer	0.00117	0.0309	CbGeAlD
Methotrexate—FOLR1—bronchus—esophageal cancer	0.00115	0.0304	CbGeAlD
Methotrexate—Gastrointestinal toxicity—Capecitabine—esophageal cancer	0.00109	0.0228	CcSEcCtD
Methotrexate—Pulmonary toxicity—Cisplatin—esophageal cancer	0.00107	0.0223	CcSEcCtD
Methotrexate—FOLR1—trachea—esophageal cancer	0.00103	0.0273	CbGeAlD
Methotrexate—Extravasation—Carboplatin—esophageal cancer	0.000951	0.0198	CcSEcCtD
Methotrexate—Azoospermia—Cisplatin—esophageal cancer	0.000903	0.0188	CcSEcCtD
Methotrexate—Mood alteration NOS—Capecitabine—esophageal cancer	0.000894	0.0186	CcSEcCtD
Methotrexate—Fibrosis—Cisplatin—esophageal cancer	0.000851	0.0178	CcSEcCtD
Methotrexate—SLC19A1—digestive system—esophageal cancer	0.000777	0.0206	CbGeAlD
Methotrexate—GGH—bronchus—esophageal cancer	0.000762	0.0202	CbGeAlD
Methotrexate—GGH—smooth muscle tissue—esophageal cancer	0.000746	0.0198	CbGeAlD
Methotrexate—FOLR1—lung—esophageal cancer	0.00074	0.0196	CbGeAlD
Methotrexate—MTHFR—neck—esophageal cancer	0.000719	0.0191	CbGeAlD
Methotrexate—Skin necrosis—Cisplatin—esophageal cancer	0.000696	0.0145	CcSEcCtD
Methotrexate—GGH—trachea—esophageal cancer	0.000685	0.0182	CbGeAlD
Methotrexate—FPGS—bronchus—esophageal cancer	0.00067	0.0178	CbGeAlD
Methotrexate—Thromboembolic event—Capecitabine—esophageal cancer	0.000666	0.0139	CcSEcCtD
Methotrexate—ATIC—epithelium—esophageal cancer	0.000658	0.0175	CbGeAlD
Methotrexate—SLC19A1—lung—esophageal cancer	0.000649	0.0172	CbGeAlD
Methotrexate—Leucovorin—ABCC2—esophageal cancer	0.000642	0.608	CrCbGaD
Methotrexate—ATIC—smooth muscle tissue—esophageal cancer	0.000634	0.0168	CbGeAlD
Methotrexate—Fibrosis—Capecitabine—esophageal cancer	0.000628	0.0131	CcSEcCtD
Methotrexate—Neurotoxicity—Cisplatin—esophageal cancer	0.000627	0.0131	CcSEcCtD
Methotrexate—PGD—neck—esophageal cancer	0.000625	0.0166	CbGeAlD
Methotrexate—SLCO4C1—trachea—esophageal cancer	0.000607	0.0161	CbGeAlD
Methotrexate—FPGS—trachea—esophageal cancer	0.000602	0.016	CbGeAlD
Methotrexate—SLC46A1—digestive system—esophageal cancer	0.000599	0.0159	CbGeAlD
Methotrexate—GGH—digestive system—esophageal cancer	0.000589	0.0156	CbGeAlD
Methotrexate—Enteritis—Capecitabine—esophageal cancer	0.000525	0.0109	CcSEcCtD
Methotrexate—FPGS—digestive system—esophageal cancer	0.000518	0.0137	CbGeAlD
Methotrexate—ATIC—digestive system—esophageal cancer	0.000501	0.0133	CbGeAlD
Methotrexate—GGH—lung—esophageal cancer	0.000492	0.0131	CbGeAlD
Methotrexate—MTHFR—bronchus—esophageal cancer	0.000482	0.0128	CbGeAlD
Methotrexate—SLCO3A1—bronchus—esophageal cancer	0.000474	0.0126	CbGeAlD
Methotrexate—Neurotoxicity—Capecitabine—esophageal cancer	0.000463	0.00964	CcSEcCtD
Methotrexate—SLC19A1—lymph node—esophageal cancer	0.000444	0.0118	CbGeAlD
Methotrexate—TYMS—bronchus—esophageal cancer	0.00044	0.0117	CbGeAlD
Methotrexate—Rales—Capecitabine—esophageal cancer	0.000437	0.00912	CcSEcCtD
Methotrexate—Pericardial effusion—Capecitabine—esophageal cancer	0.000437	0.00912	CcSEcCtD
Methotrexate—SLCO4C1—lung—esophageal cancer	0.000436	0.0116	CbGeAlD
Methotrexate—DHFR—bronchus—esophageal cancer	0.000435	0.0116	CbGeAlD
Methotrexate—FPGS—lung—esophageal cancer	0.000432	0.0115	CbGeAlD
Methotrexate—TYMS—smooth muscle tissue—esophageal cancer	0.00043	0.0114	CbGeAlD
Methotrexate—SLCO1B3—lung—esophageal cancer	0.000424	0.0112	CbGeAlD
Methotrexate—PGD—bronchus—esophageal cancer	0.000419	0.0111	CbGeAlD
Methotrexate—ATIC—lung—esophageal cancer	0.000418	0.0111	CbGeAlD
Methotrexate—Tetrahydrofolic acid—ABCC2—esophageal cancer	0.000414	0.392	CrCbGaD
Methotrexate—PGD—smooth muscle tissue—esophageal cancer	0.000409	0.0109	CbGeAlD
Methotrexate—SLC22A11—digestive system—esophageal cancer	0.000404	0.0107	CbGeAlD
Methotrexate—Febrile neutropenia—Cisplatin—esophageal cancer	0.000404	0.00843	CcSEcCtD
Methotrexate—SLC16A1—epithelium—esophageal cancer	0.000397	0.0105	CbGeAlD
Methotrexate—SLC22A7—digestive system—esophageal cancer	0.000395	0.0105	CbGeAlD
Methotrexate—DHFR—trachea—esophageal cancer	0.000391	0.0104	CbGeAlD
Methotrexate—PGD—trachea—esophageal cancer	0.000376	0.00997	CbGeAlD
Methotrexate—MTHFR—digestive system—esophageal cancer	0.000372	0.00988	CbGeAlD
Methotrexate—AOX1—bronchus—esophageal cancer	0.000369	0.00978	CbGeAlD
Methotrexate—ABCC10—bronchus—esophageal cancer	0.000359	0.00952	CbGeAlD
Methotrexate—Sudden death—Capecitabine—esophageal cancer	0.00035	0.00731	CcSEcCtD
Methotrexate—SLC46A1—lymph node—esophageal cancer	0.000342	0.00907	CbGeAlD
Methotrexate—TYMS—digestive system—esophageal cancer	0.00034	0.00901	CbGeAlD
Methotrexate—GGH—lymph node—esophageal cancer	0.000336	0.00893	CbGeAlD
Methotrexate—DHFR—digestive system—esophageal cancer	0.000336	0.00892	CbGeAlD
Methotrexate—AOX1—trachea—esophageal cancer	0.000331	0.00878	CbGeAlD
Methotrexate—Mucosal inflammation—Capecitabine—esophageal cancer	0.000324	0.00675	CcSEcCtD
Methotrexate—PGD—digestive system—esophageal cancer	0.000323	0.00858	CbGeAlD
Methotrexate—ABCC10—trachea—esophageal cancer	0.000322	0.00855	CbGeAlD
Methotrexate—Hepatotoxicity—Cisplatin—esophageal cancer	0.000315	0.00657	CcSEcCtD
Methotrexate—MTHFR—lung—esophageal cancer	0.000311	0.00825	CbGeAlD
Methotrexate—Necrosis—Cisplatin—esophageal cancer	0.00031	0.00646	CcSEcCtD
Methotrexate—Abscess—Cisplatin—esophageal cancer	0.000307	0.00641	CcSEcCtD
Methotrexate—SLCO3A1—lung—esophageal cancer	0.000306	0.00812	CbGeAlD
Methotrexate—SLC16A1—digestive system—esophageal cancer	0.000302	0.00801	CbGeAlD
Methotrexate—Skin hyperpigmentation—Capecitabine—esophageal cancer	0.000302	0.00629	CcSEcCtD
Methotrexate—Febrile neutropenia—Capecitabine—esophageal cancer	0.000298	0.00622	CcSEcCtD
Methotrexate—ABCC4—bronchus—esophageal cancer	0.000298	0.0079	CbGeAlD
Methotrexate—FPGS—lymph node—esophageal cancer	0.000296	0.00785	CbGeAlD
Methotrexate—Deep vein thrombosis—Capecitabine—esophageal cancer	0.000295	0.00615	CcSEcCtD
Methotrexate—Infection—Carboplatin—esophageal cancer	0.000294	0.00613	CcSEcCtD
Methotrexate—SLCO1B1—digestive system—esophageal cancer	0.000294	0.00779	CbGeAlD
Methotrexate—ATIC—lymph node—esophageal cancer	0.000286	0.00759	CbGeAlD
Methotrexate—AOX1—digestive system—esophageal cancer	0.000285	0.00756	CbGeAlD
Methotrexate—TYMS—lung—esophageal cancer	0.000284	0.00753	CbGeAlD
Methotrexate—DHFR—lung—esophageal cancer	0.000281	0.00745	CbGeAlD
Methotrexate—Encephalopathy—Capecitabine—esophageal cancer	0.000279	0.00583	CcSEcCtD
Methotrexate—Embolism—Capecitabine—esophageal cancer	0.000279	0.00583	CcSEcCtD
Methotrexate—Extravasation—Cisplatin—esophageal cancer	0.000279	0.00581	CcSEcCtD
Methotrexate—ABCC3—digestive system—esophageal cancer	0.000279	0.00739	CbGeAlD
Methotrexate—ABCC10—digestive system—esophageal cancer	0.000277	0.00736	CbGeAlD
Methotrexate—Nail disorder—Capecitabine—esophageal cancer	0.000276	0.00577	CcSEcCtD
Methotrexate—Aphasia—Capecitabine—esophageal cancer	0.000276	0.00577	CcSEcCtD
Methotrexate—PGD—lung—esophageal cancer	0.00027	0.00716	CbGeAlD
Methotrexate—Bone marrow depression—Capecitabine—esophageal cancer	0.000266	0.00554	CcSEcCtD
Methotrexate—Hyperuricaemia—Cisplatin—esophageal cancer	0.000262	0.00547	CcSEcCtD
Methotrexate—Haematemesis—Capecitabine—esophageal cancer	0.000258	0.00538	CcSEcCtD
Methotrexate—Dysarthria—Cisplatin—esophageal cancer	0.000257	0.00536	CcSEcCtD
Methotrexate—Ulcer—Cisplatin—esophageal cancer	0.000257	0.00536	CcSEcCtD
Methotrexate—ABCC1—bronchus—esophageal cancer	0.000254	0.00673	CbGeAlD
Methotrexate—Pain—Carboplatin—esophageal cancer	0.000253	0.00528	CcSEcCtD
Methotrexate—SLC16A1—lung—esophageal cancer	0.000252	0.00669	CbGeAlD
Methotrexate—Blood uric acid increased—Cisplatin—esophageal cancer	0.000248	0.00517	CcSEcCtD
Methotrexate—SLCO1A2—digestive system—esophageal cancer	0.000239	0.00634	CbGeAlD
Methotrexate—Herpes zoster—Capecitabine—esophageal cancer	0.000238	0.00497	CcSEcCtD
Methotrexate—AOX1—lung—esophageal cancer	0.000238	0.00631	CbGeAlD
Methotrexate—SLCO1C1—lymph node—esophageal cancer	0.000238	0.00631	CbGeAlD
Methotrexate—Pleural effusion—Capecitabine—esophageal cancer	0.000234	0.00488	CcSEcCtD
Methotrexate—Body temperature increased—Carboplatin—esophageal cancer	0.000234	0.00488	CcSEcCtD
Methotrexate—ABCC3—lung—esophageal cancer	0.000233	0.00617	CbGeAlD
Methotrexate—Skin exfoliation—Cisplatin—esophageal cancer	0.000232	0.00484	CcSEcCtD
Methotrexate—Hepatotoxicity—Capecitabine—esophageal cancer	0.000232	0.00484	CcSEcCtD
Methotrexate—Fungal infection—Capecitabine—esophageal cancer	0.000232	0.00484	CcSEcCtD
Methotrexate—ABCC10—lung—esophageal cancer	0.000232	0.00614	CbGeAlD
Methotrexate—Skin ulcer—Capecitabine—esophageal cancer	0.00023	0.0048	CcSEcCtD
Methotrexate—ABCC4—digestive system—esophageal cancer	0.00023	0.0061	CbGeAlD
Methotrexate—ABCC1—trachea—esophageal cancer	0.000228	0.00605	CbGeAlD
Methotrexate—ABCC2—digestive system—esophageal cancer	0.000223	0.00591	CbGeAlD
Methotrexate—Petechiae—Capecitabine—esophageal cancer	0.000218	0.00455	CcSEcCtD
Methotrexate—MTHFR—lymph node—esophageal cancer	0.000213	0.00564	CbGeAlD
Methotrexate—SLCO3A1—lymph node—esophageal cancer	0.000209	0.00555	CbGeAlD
Methotrexate—Proteinuria—Capecitabine—esophageal cancer	0.000204	0.00426	CcSEcCtD
Methotrexate—Protein urine present—Capecitabine—esophageal cancer	0.000201	0.0042	CcSEcCtD
Methotrexate—Polyuria—Cisplatin—esophageal cancer	0.000201	0.00419	CcSEcCtD
Methotrexate—Musculoskeletal stiffness—Capecitabine—esophageal cancer	0.0002	0.00417	CcSEcCtD
Methotrexate—SLCO1A2—lung—esophageal cancer	0.0002	0.00529	CbGeAlD
Methotrexate—Skin discolouration—Capecitabine—esophageal cancer	0.000199	0.00414	CcSEcCtD
Methotrexate—Hyperbilirubinaemia—Capecitabine—esophageal cancer	0.000197	0.00411	CcSEcCtD
Methotrexate—Herpes simplex—Capecitabine—esophageal cancer	0.000195	0.00406	CcSEcCtD
Methotrexate—TYMS—lymph node—esophageal cancer	0.000194	0.00515	CbGeAlD
Methotrexate—DHFR—lymph node—esophageal cancer	0.000192	0.0051	CbGeAlD
Methotrexate—ABCC4—lung—esophageal cancer	0.000192	0.0051	CbGeAlD
Methotrexate—Renal failure acute—Cisplatin—esophageal cancer	0.000191	0.00399	CcSEcCtD
Methotrexate—Ulcer—Capecitabine—esophageal cancer	0.00019	0.00395	CcSEcCtD
Methotrexate—Dysarthria—Capecitabine—esophageal cancer	0.00019	0.00395	CcSEcCtD
Methotrexate—Inflammation—Capecitabine—esophageal cancer	0.000185	0.00386	CcSEcCtD
Methotrexate—PGD—lymph node—esophageal cancer	0.000185	0.0049	CbGeAlD
Methotrexate—Anaphylactoid reaction—Cisplatin—esophageal cancer	0.000182	0.0038	CcSEcCtD
Methotrexate—Cerebrovascular accident—Cisplatin—esophageal cancer	0.00018	0.00376	CcSEcCtD
Methotrexate—Pulmonary embolism—Capecitabine—esophageal cancer	0.000179	0.00374	CcSEcCtD
Methotrexate—Melaena—Capecitabine—esophageal cancer	0.000175	0.00365	CcSEcCtD
Methotrexate—Depressed level of consciousness—Capecitabine—esophageal cancer	0.000173	0.00361	CcSEcCtD
Methotrexate—SLC16A1—lymph node—esophageal cancer	0.000172	0.00457	CbGeAlD
Methotrexate—Skin exfoliation—Capecitabine—esophageal cancer	0.000171	0.00357	CcSEcCtD
Methotrexate—Irritability—Cisplatin—esophageal cancer	0.000169	0.00351	CcSEcCtD
Methotrexate—ABCC1—lung—esophageal cancer	0.000164	0.00434	CbGeAlD
Methotrexate—AOX1—lymph node—esophageal cancer	0.000163	0.00432	CbGeAlD
Methotrexate—Urine output increased—Capecitabine—esophageal cancer	0.000162	0.00338	CcSEcCtD
Methotrexate—Neoplasm—Capecitabine—esophageal cancer	0.000162	0.00338	CcSEcCtD
Methotrexate—Ecchymosis—Capecitabine—esophageal cancer	0.000162	0.00338	CcSEcCtD
Methotrexate—Mouth ulceration—Capecitabine—esophageal cancer	0.000162	0.00338	CcSEcCtD
Methotrexate—Breast disorder—Cisplatin—esophageal cancer	0.00016	0.00333	CcSEcCtD
Methotrexate—ABCC3—lymph node—esophageal cancer	0.000159	0.00422	CbGeAlD
Methotrexate—ABCC10—lymph node—esophageal cancer	0.000158	0.0042	CbGeAlD
Methotrexate—Sepsis—Capecitabine—esophageal cancer	0.000156	0.00325	CcSEcCtD
Methotrexate—Thrombophlebitis—Capecitabine—esophageal cancer	0.00015	0.00314	CcSEcCtD
Methotrexate—Diabetes mellitus—Capecitabine—esophageal cancer	0.00015	0.00312	CcSEcCtD
Methotrexate—Pancreatitis—Cisplatin—esophageal cancer	0.00015	0.00312	CcSEcCtD
Methotrexate—Polyuria—Capecitabine—esophageal cancer	0.000148	0.00309	CcSEcCtD
Methotrexate—Photosensitivity—Capecitabine—esophageal cancer	0.000148	0.00309	CcSEcCtD
Methotrexate—Abdominal discomfort—Cisplatin—esophageal cancer	0.000146	0.00305	CcSEcCtD
Methotrexate—Pancytopenia—Cisplatin—esophageal cancer	0.000145	0.00302	CcSEcCtD
Methotrexate—Hepatic failure—Capecitabine—esophageal cancer	0.000145	0.00302	CcSEcCtD
Methotrexate—Renal failure acute—Capecitabine—esophageal cancer	0.000141	0.00294	CcSEcCtD
Methotrexate—Dermatitis exfoliative—Capecitabine—esophageal cancer	0.000138	0.00288	CcSEcCtD
Methotrexate—ALB—lymph node—esophageal cancer	0.000136	0.0036	CbGeAlD
Methotrexate—ABCG2—lung—esophageal cancer	0.000136	0.0036	CbGeAlD
Methotrexate—Renal failure—Cisplatin—esophageal cancer	0.000134	0.00279	CcSEcCtD
Methotrexate—Cerebrovascular accident—Capecitabine—esophageal cancer	0.000133	0.00277	CcSEcCtD
Methotrexate—Lethargy—Capecitabine—esophageal cancer	0.000133	0.00277	CcSEcCtD
Methotrexate—Stomatitis—Cisplatin—esophageal cancer	0.000133	0.00277	CcSEcCtD
Methotrexate—Conjunctivitis—Cisplatin—esophageal cancer	0.000132	0.00276	CcSEcCtD
Methotrexate—ABCC4—lymph node—esophageal cancer	0.000131	0.00349	CbGeAlD
Methotrexate—Osteoarthritis—Capecitabine—esophageal cancer	0.00013	0.00271	CcSEcCtD
Methotrexate—Hepatobiliary disease—Cisplatin—esophageal cancer	0.000129	0.00268	CcSEcCtD
Methotrexate—ABCC2—lymph node—esophageal cancer	0.000127	0.00337	CbGeAlD
Methotrexate—Irritability—Capecitabine—esophageal cancer	0.000124	0.00259	CcSEcCtD
Methotrexate—Mood swings—Capecitabine—esophageal cancer	0.000123	0.00257	CcSEcCtD
Methotrexate—Ataxia—Capecitabine—esophageal cancer	0.000122	0.00255	CcSEcCtD
Methotrexate—Urinary tract disorder—Cisplatin—esophageal cancer	0.000121	0.00252	CcSEcCtD
Methotrexate—Liver function test abnormal—Capecitabine—esophageal cancer	0.00012	0.00251	CcSEcCtD
Methotrexate—Urethral disorder—Cisplatin—esophageal cancer	0.00012	0.0025	CcSEcCtD
Methotrexate—Visual impairment—Cisplatin—esophageal cancer	0.000118	0.00246	CcSEcCtD
Methotrexate—Breast disorder—Capecitabine—esophageal cancer	0.000118	0.00245	CcSEcCtD
Methotrexate—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.000117	0.00244	CcSEcCtD
Methotrexate—Eye disorder—Cisplatin—esophageal cancer	0.000114	0.00238	CcSEcCtD
Methotrexate—Tinnitus—Cisplatin—esophageal cancer	0.000114	0.00238	CcSEcCtD
Methotrexate—Cardiac disorder—Cisplatin—esophageal cancer	0.000113	0.00236	CcSEcCtD
Methotrexate—Asthma—Capecitabine—esophageal cancer	0.000113	0.00235	CcSEcCtD
Methotrexate—ABCC1—lymph node—esophageal cancer	0.000112	0.00297	CbGeAlD
Methotrexate—Immune system disorder—Cisplatin—esophageal cancer	0.00011	0.0023	CcSEcCtD
Methotrexate—Mediastinal disorder—Cisplatin—esophageal cancer	0.00011	0.0023	CcSEcCtD
Methotrexate—Alopecia—Cisplatin—esophageal cancer	0.000108	0.00225	CcSEcCtD
Methotrexate—Abdominal discomfort—Capecitabine—esophageal cancer	0.000108	0.00225	CcSEcCtD
Methotrexate—Pancytopenia—Capecitabine—esophageal cancer	0.000107	0.00223	CcSEcCtD
Methotrexate—Malnutrition—Cisplatin—esophageal cancer	0.000106	0.00222	CcSEcCtD
Methotrexate—Erythema—Cisplatin—esophageal cancer	0.000106	0.00222	CcSEcCtD
Methotrexate—ABCB1—epithelium—esophageal cancer	0.000105	0.00279	CbGeAlD
Methotrexate—Neutropenia—Capecitabine—esophageal cancer	0.000105	0.00219	CcSEcCtD
Methotrexate—Dysuria—Capecitabine—esophageal cancer	0.000105	0.00219	CcSEcCtD
Methotrexate—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000105	0.00218	CcSEcCtD
Methotrexate—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000103	0.00214	CcSEcCtD
Methotrexate—Pneumonia—Capecitabine—esophageal cancer	0.000101	0.0021	CcSEcCtD
Methotrexate—Infestation NOS—Capecitabine—esophageal cancer	0.0001	0.00209	CcSEcCtD
Methotrexate—Infestation—Capecitabine—esophageal cancer	0.0001	0.00209	CcSEcCtD
Methotrexate—Vision blurred—Cisplatin—esophageal cancer	0.0001	0.00209	CcSEcCtD
Methotrexate—Depression—Capecitabine—esophageal cancer	0.0001	0.00209	CcSEcCtD
Methotrexate—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	9.95e-05	0.00207	CcSEcCtD
Methotrexate—Ill-defined disorder—Cisplatin—esophageal cancer	9.87e-05	0.00206	CcSEcCtD
Methotrexate—Renal failure—Capecitabine—esophageal cancer	9.86e-05	0.00206	CcSEcCtD
Methotrexate—Anaemia—Cisplatin—esophageal cancer	9.83e-05	0.00205	CcSEcCtD
Methotrexate—Stomatitis—Capecitabine—esophageal cancer	9.78e-05	0.00204	CcSEcCtD
Methotrexate—Conjunctivitis—Capecitabine—esophageal cancer	9.75e-05	0.00203	CcSEcCtD
Methotrexate—Malaise—Cisplatin—esophageal cancer	9.59e-05	0.002	CcSEcCtD
Methotrexate—Haematuria—Capecitabine—esophageal cancer	9.57e-05	0.00199	CcSEcCtD
Methotrexate—Leukopenia—Cisplatin—esophageal cancer	9.52e-05	0.00199	CcSEcCtD
Methotrexate—Hepatobiliary disease—Capecitabine—esophageal cancer	9.49e-05	0.00198	CcSEcCtD
Methotrexate—Epistaxis—Capecitabine—esophageal cancer	9.46e-05	0.00197	CcSEcCtD
Methotrexate—Agranulocytosis—Capecitabine—esophageal cancer	9.36e-05	0.00195	CcSEcCtD
Methotrexate—ABCB1—trachea—esophageal cancer	9.3e-05	0.00247	CbGeAlD
Methotrexate—ABCG2—lymph node—esophageal cancer	9.27e-05	0.00246	CbGeAlD
Methotrexate—Convulsion—Cisplatin—esophageal cancer	9.21e-05	0.00192	CcSEcCtD
Methotrexate—Myalgia—Cisplatin—esophageal cancer	9.05e-05	0.00189	CcSEcCtD
Methotrexate—Haemoglobin—Capecitabine—esophageal cancer	9.05e-05	0.00189	CcSEcCtD
Methotrexate—Haemorrhage—Capecitabine—esophageal cancer	9.01e-05	0.00188	CcSEcCtD
Methotrexate—Hepatitis—Capecitabine—esophageal cancer	9.01e-05	0.00188	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	8.99e-05	0.00188	CcSEcCtD
Methotrexate—Discomfort—Cisplatin—esophageal cancer	8.95e-05	0.00187	CcSEcCtD
Methotrexate—Pharyngitis—Capecitabine—esophageal cancer	8.94e-05	0.00186	CcSEcCtD
Methotrexate—Urinary tract disorder—Capecitabine—esophageal cancer	8.89e-05	0.00185	CcSEcCtD
Methotrexate—Urethral disorder—Capecitabine—esophageal cancer	8.83e-05	0.00184	CcSEcCtD
Methotrexate—Anaphylactic shock—Cisplatin—esophageal cancer	8.68e-05	0.00181	CcSEcCtD
Methotrexate—Visual impairment—Capecitabine—esophageal cancer	8.68e-05	0.00181	CcSEcCtD
Methotrexate—Infection—Cisplatin—esophageal cancer	8.62e-05	0.0018	CcSEcCtD
Methotrexate—Erythema multiforme—Capecitabine—esophageal cancer	8.51e-05	0.00178	CcSEcCtD
Methotrexate—Nervous system disorder—Cisplatin—esophageal cancer	8.51e-05	0.00177	CcSEcCtD
Methotrexate—Thrombocytopenia—Cisplatin—esophageal cancer	8.5e-05	0.00177	CcSEcCtD
Methotrexate—Skin disorder—Cisplatin—esophageal cancer	8.43e-05	0.00176	CcSEcCtD
Methotrexate—Eye disorder—Capecitabine—esophageal cancer	8.42e-05	0.00175	CcSEcCtD
Methotrexate—Tinnitus—Capecitabine—esophageal cancer	8.4e-05	0.00175	CcSEcCtD
Methotrexate—Hyperhidrosis—Cisplatin—esophageal cancer	8.39e-05	0.00175	CcSEcCtD
Methotrexate—Cardiac disorder—Capecitabine—esophageal cancer	8.36e-05	0.00174	CcSEcCtD
Methotrexate—Anorexia—Cisplatin—esophageal cancer	8.27e-05	0.00173	CcSEcCtD
Methotrexate—Angiopathy—Capecitabine—esophageal cancer	8.17e-05	0.0017	CcSEcCtD
Methotrexate—Immune system disorder—Capecitabine—esophageal cancer	8.13e-05	0.0017	CcSEcCtD
Methotrexate—Mediastinal disorder—Capecitabine—esophageal cancer	8.12e-05	0.00169	CcSEcCtD
Methotrexate—Hypotension—Cisplatin—esophageal cancer	8.11e-05	0.00169	CcSEcCtD
Methotrexate—Chills—Capecitabine—esophageal cancer	8.08e-05	0.00168	CcSEcCtD
Methotrexate—ABCB1—digestive system—esophageal cancer	8e-05	0.00212	CbGeAlD
Methotrexate—Alopecia—Capecitabine—esophageal cancer	7.96e-05	0.00166	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Cisplatin—esophageal cancer	7.91e-05	0.00165	CcSEcCtD
Methotrexate—Mental disorder—Capecitabine—esophageal cancer	7.89e-05	0.00165	CcSEcCtD
Methotrexate—Malnutrition—Capecitabine—esophageal cancer	7.84e-05	0.00163	CcSEcCtD
Methotrexate—Erythema—Capecitabine—esophageal cancer	7.84e-05	0.00163	CcSEcCtD
Methotrexate—Paraesthesia—Cisplatin—esophageal cancer	7.79e-05	0.00163	CcSEcCtD
Methotrexate—Dyspnoea—Cisplatin—esophageal cancer	7.74e-05	0.00161	CcSEcCtD
Methotrexate—Dysgeusia—Capecitabine—esophageal cancer	7.68e-05	0.0016	CcSEcCtD
Methotrexate—Back pain—Capecitabine—esophageal cancer	7.58e-05	0.00158	CcSEcCtD
Methotrexate—Decreased appetite—Cisplatin—esophageal cancer	7.55e-05	0.00157	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Cisplatin—esophageal cancer	7.49e-05	0.00156	CcSEcCtD
Methotrexate—Pain—Cisplatin—esophageal cancer	7.42e-05	0.00155	CcSEcCtD
Methotrexate—Vision blurred—Capecitabine—esophageal cancer	7.39e-05	0.00154	CcSEcCtD
Methotrexate—Ill-defined disorder—Capecitabine—esophageal cancer	7.27e-05	0.00152	CcSEcCtD
Methotrexate—Anaemia—Capecitabine—esophageal cancer	7.25e-05	0.00151	CcSEcCtD
Methotrexate—Feeling abnormal—Cisplatin—esophageal cancer	7.15e-05	0.00149	CcSEcCtD
Methotrexate—Malaise—Capecitabine—esophageal cancer	7.07e-05	0.00147	CcSEcCtD
Methotrexate—Vertigo—Capecitabine—esophageal cancer	7.04e-05	0.00147	CcSEcCtD
Methotrexate—Leukopenia—Capecitabine—esophageal cancer	7.02e-05	0.00146	CcSEcCtD
Methotrexate—Body temperature increased—Cisplatin—esophageal cancer	6.86e-05	0.00143	CcSEcCtD
Methotrexate—Cough—Capecitabine—esophageal cancer	6.84e-05	0.00143	CcSEcCtD
Methotrexate—ABCB1—lung—esophageal cancer	6.69e-05	0.00177	CbGeAlD
Methotrexate—Chest pain—Capecitabine—esophageal cancer	6.67e-05	0.00139	CcSEcCtD
Methotrexate—Myalgia—Capecitabine—esophageal cancer	6.67e-05	0.00139	CcSEcCtD
Methotrexate—Arthralgia—Capecitabine—esophageal cancer	6.67e-05	0.00139	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	6.63e-05	0.00138	CcSEcCtD
Methotrexate—Discomfort—Capecitabine—esophageal cancer	6.59e-05	0.00138	CcSEcCtD
Methotrexate—Confusional state—Capecitabine—esophageal cancer	6.45e-05	0.00135	CcSEcCtD
Methotrexate—Hypersensitivity—Cisplatin—esophageal cancer	6.39e-05	0.00133	CcSEcCtD
Methotrexate—Infection—Capecitabine—esophageal cancer	6.36e-05	0.00133	CcSEcCtD
Methotrexate—Nervous system disorder—Capecitabine—esophageal cancer	6.27e-05	0.00131	CcSEcCtD
Methotrexate—Thrombocytopenia—Capecitabine—esophageal cancer	6.26e-05	0.00131	CcSEcCtD
Methotrexate—Asthenia—Cisplatin—esophageal cancer	6.23e-05	0.0013	CcSEcCtD
Methotrexate—Skin disorder—Capecitabine—esophageal cancer	6.21e-05	0.0013	CcSEcCtD
Methotrexate—Hyperhidrosis—Capecitabine—esophageal cancer	6.19e-05	0.00129	CcSEcCtD
Methotrexate—Anorexia—Capecitabine—esophageal cancer	6.1e-05	0.00127	CcSEcCtD
Methotrexate—Hypotension—Capecitabine—esophageal cancer	5.98e-05	0.00125	CcSEcCtD
Methotrexate—Diarrhoea—Cisplatin—esophageal cancer	5.94e-05	0.00124	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Capecitabine—esophageal cancer	5.83e-05	0.00122	CcSEcCtD
Methotrexate—Insomnia—Capecitabine—esophageal cancer	5.79e-05	0.00121	CcSEcCtD
Methotrexate—Paraesthesia—Capecitabine—esophageal cancer	5.75e-05	0.0012	CcSEcCtD
Methotrexate—Dyspnoea—Capecitabine—esophageal cancer	5.7e-05	0.00119	CcSEcCtD
Methotrexate—Dyspepsia—Capecitabine—esophageal cancer	5.63e-05	0.00117	CcSEcCtD
Methotrexate—Decreased appetite—Capecitabine—esophageal cancer	5.56e-05	0.00116	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Capecitabine—esophageal cancer	5.52e-05	0.00115	CcSEcCtD
Methotrexate—Vomiting—Cisplatin—esophageal cancer	5.52e-05	0.00115	CcSEcCtD
Methotrexate—Fatigue—Capecitabine—esophageal cancer	5.52e-05	0.00115	CcSEcCtD
Methotrexate—Rash—Cisplatin—esophageal cancer	5.47e-05	0.00114	CcSEcCtD
Methotrexate—Pain—Capecitabine—esophageal cancer	5.47e-05	0.00114	CcSEcCtD
Methotrexate—Dermatitis—Cisplatin—esophageal cancer	5.47e-05	0.00114	CcSEcCtD
Methotrexate—Feeling abnormal—Capecitabine—esophageal cancer	5.27e-05	0.0011	CcSEcCtD
Methotrexate—Gastrointestinal pain—Capecitabine—esophageal cancer	5.23e-05	0.00109	CcSEcCtD
Methotrexate—Nausea—Cisplatin—esophageal cancer	5.16e-05	0.00108	CcSEcCtD
Methotrexate—Urticaria—Capecitabine—esophageal cancer	5.08e-05	0.00106	CcSEcCtD
Methotrexate—Abdominal pain—Capecitabine—esophageal cancer	5.06e-05	0.00105	CcSEcCtD
Methotrexate—Body temperature increased—Capecitabine—esophageal cancer	5.06e-05	0.00105	CcSEcCtD
Methotrexate—Hypersensitivity—Capecitabine—esophageal cancer	4.71e-05	0.000983	CcSEcCtD
Methotrexate—Asthenia—Capecitabine—esophageal cancer	4.59e-05	0.000957	CcSEcCtD
Methotrexate—ABCB1—lymph node—esophageal cancer	4.57e-05	0.00121	CbGeAlD
Methotrexate—Pruritus—Capecitabine—esophageal cancer	4.53e-05	0.000944	CcSEcCtD
Methotrexate—Diarrhoea—Capecitabine—esophageal cancer	4.38e-05	0.000913	CcSEcCtD
Methotrexate—Dizziness—Capecitabine—esophageal cancer	4.23e-05	0.000882	CcSEcCtD
Methotrexate—Vomiting—Capecitabine—esophageal cancer	4.07e-05	0.000848	CcSEcCtD
Methotrexate—Rash—Capecitabine—esophageal cancer	4.03e-05	0.000841	CcSEcCtD
Methotrexate—Dermatitis—Capecitabine—esophageal cancer	4.03e-05	0.00084	CcSEcCtD
Methotrexate—Headache—Capecitabine—esophageal cancer	4.01e-05	0.000836	CcSEcCtD
Methotrexate—Nausea—Capecitabine—esophageal cancer	3.8e-05	0.000792	CcSEcCtD
Methotrexate—ABCB1—Metabolism—CA1—esophageal cancer	4.92e-06	7.01e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—SLC10A2—esophageal cancer	4.92e-06	7.01e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—GSTT1—esophageal cancer	4.91e-06	6.99e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	4.9e-06	6.98e-05	CbGpPWpGaD
Methotrexate—ABCC2—Transmembrane transport of small molecules—CREBBP—esophageal cancer	4.9e-06	6.97e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	4.86e-06	6.91e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—CYP2A6—esophageal cancer	4.86e-06	6.91e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—ENO1—esophageal cancer	4.84e-06	6.9e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PTGS1—esophageal cancer	4.84e-06	6.9e-05	CbGpPWpGaD
Methotrexate—PGD—Disease—MYC—esophageal cancer	4.84e-06	6.89e-05	CbGpPWpGaD
Methotrexate—ABCC1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	4.84e-06	6.89e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	4.84e-06	6.89e-05	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—PIK3CA—esophageal cancer	4.83e-06	6.88e-05	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—PIK3CA—esophageal cancer	4.83e-06	6.88e-05	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—MYC—esophageal cancer	4.83e-06	6.87e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—NOS3—esophageal cancer	4.82e-06	6.86e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—ABCB1—esophageal cancer	4.8e-06	6.83e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—CREBBP—esophageal cancer	4.78e-06	6.81e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—ALDH2—esophageal cancer	4.78e-06	6.81e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PLCE1—esophageal cancer	4.78e-06	6.8e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ADH7—esophageal cancer	4.78e-06	6.8e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PSME1—esophageal cancer	4.77e-06	6.8e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PSME2—esophageal cancer	4.77e-06	6.8e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	4.75e-06	6.76e-05	CbGpPWpGaD
Methotrexate—PGD—Disease—EGFR—esophageal cancer	4.74e-06	6.74e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	4.72e-06	6.72e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—NOS3—esophageal cancer	4.71e-06	6.7e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—ABL1—esophageal cancer	4.69e-06	6.68e-05	CbGpPWpGaD
Methotrexate—PGD—Metabolism—EP300—esophageal cancer	4.65e-06	6.63e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	4.63e-06	6.6e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PTGS1—esophageal cancer	4.6e-06	6.55e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—ENO1—esophageal cancer	4.6e-06	6.55e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	4.6e-06	6.55e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—CYP1B1—esophageal cancer	4.58e-06	6.52e-05	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—EP300—esophageal cancer	4.57e-06	6.51e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—GSTT1—esophageal cancer	4.55e-06	6.48e-05	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—TP53—esophageal cancer	4.54e-06	6.47e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PSME1—esophageal cancer	4.54e-06	6.46e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PSME2—esophageal cancer	4.54e-06	6.46e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—PIK3CA—esophageal cancer	4.53e-06	6.45e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—HMOX1—esophageal cancer	4.51e-06	6.42e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—CREBBP—esophageal cancer	4.51e-06	6.42e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—ERBB2—esophageal cancer	4.51e-06	6.42e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CA2—esophageal cancer	4.5e-06	6.41e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CYP2A6—esophageal cancer	4.5e-06	6.4e-05	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—PIK3CA—esophageal cancer	4.49e-06	6.4e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	4.42e-06	6.3e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—PTGS2—esophageal cancer	4.41e-06	6.28e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—CREBBP—esophageal cancer	4.4e-06	6.27e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—ERBB2—esophageal cancer	4.4e-06	6.27e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—TP53—esophageal cancer	4.39e-06	6.24e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—ABCB1—esophageal cancer	4.33e-06	6.16e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—PTGS2—esophageal cancer	4.31e-06	6.13e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—CYP19A1—esophageal cancer	4.3e-06	6.13e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	4.29e-06	6.11e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—NOS3—esophageal cancer	4.28e-06	6.1e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—TGFBR2—esophageal cancer	4.28e-06	6.09e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PTGS1—esophageal cancer	4.26e-06	6.07e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—ENO1—esophageal cancer	4.26e-06	6.07e-05	CbGpPWpGaD
Methotrexate—ABCG2—Transmembrane transport of small molecules—CREBBP—esophageal cancer	4.26e-06	6.06e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PSME2—esophageal cancer	4.2e-06	5.98e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PSME1—esophageal cancer	4.2e-06	5.98e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ADH1B—esophageal cancer	4.19e-06	5.96e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ADH7—esophageal cancer	4.19e-06	5.96e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PLCE1—esophageal cancer	4.19e-06	5.96e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	4.17e-06	5.93e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	4.15e-06	5.91e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—CYP1B1—esophageal cancer	4.12e-06	5.86e-05	CbGpPWpGaD
Methotrexate—PGD—Disease—PIK3CA—esophageal cancer	4.11e-06	5.85e-05	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—HMOX1—esophageal cancer	4.1e-06	5.83e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—SMAD4—esophageal cancer	4.05e-06	5.77e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—NOS3—esophageal cancer	4.04e-06	5.75e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—CREBBP—esophageal cancer	4.01e-06	5.7e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—ERBB2—esophageal cancer	4.01e-06	5.7e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—TYMP—esophageal cancer	4e-06	5.7e-05	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—TP53—esophageal cancer	3.97e-06	5.65e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	3.96e-06	5.64e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	3.95e-06	5.62e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—NOS3—esophageal cancer	3.94e-06	5.61e-05	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—ABCB1—esophageal cancer	3.93e-06	5.6e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—HMOX1—esophageal cancer	3.93e-06	5.59e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—PTGS2—esophageal cancer	3.92e-06	5.58e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—CYP1B1—esophageal cancer	3.91e-06	5.57e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP26A1—esophageal cancer	3.89e-06	5.54e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—CYP19A1—esophageal cancer	3.87e-06	5.51e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—CDKN1A—esophageal cancer	3.85e-06	5.49e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	3.85e-06	5.49e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ALOX15—esophageal cancer	3.79e-06	5.4e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—ABCB1—esophageal cancer	3.77e-06	5.37e-05	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—PIK3CA—esophageal cancer	3.76e-06	5.36e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—CDKN1A—esophageal cancer	3.76e-06	5.36e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PTGS2—esophageal cancer	3.69e-06	5.26e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—CYP19A1—esophageal cancer	3.68e-06	5.24e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ADH1B—esophageal cancer	3.67e-06	5.23e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—EP300—esophageal cancer	3.67e-06	5.22e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—CREBBP—esophageal cancer	3.65e-06	5.19e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	3.63e-06	5.16e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CYP1B1—esophageal cancer	3.62e-06	5.16e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GSTO1—esophageal cancer	3.62e-06	5.15e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—TPI1—esophageal cancer	3.62e-06	5.15e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PTGS2—esophageal cancer	3.61e-06	5.13e-05	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	3.59e-06	5.11e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—NOS3—esophageal cancer	3.59e-06	5.11e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—EP300—esophageal cancer	3.58e-06	5.1e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—HMOX1—esophageal cancer	3.53e-06	5.03e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—TYMP—esophageal cancer	3.51e-06	4.99e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—CREBBP—esophageal cancer	3.5e-06	4.98e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ALDOB—esophageal cancer	3.47e-06	4.94e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	3.47e-06	4.94e-05	CbGpPWpGaD
Methotrexate—PGD—Metabolism—PIK3CA—esophageal cancer	3.44e-06	4.9e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	3.44e-06	4.9e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—CDKN1A—esophageal cancer	3.42e-06	4.87e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP26A1—esophageal cancer	3.41e-06	4.86e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CYP19A1—esophageal cancer	3.41e-06	4.85e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—ABCB1—esophageal cancer	3.39e-06	4.83e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—NOS2—esophageal cancer	3.38e-06	4.81e-05	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—PIK3CA—esophageal cancer	3.38e-06	4.81e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	3.37e-06	4.79e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—HMOX1—esophageal cancer	3.36e-06	4.78e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GAPDH—esophageal cancer	3.34e-06	4.76e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ALOX15—esophageal cancer	3.33e-06	4.73e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—HIF1A—esophageal cancer	3.31e-06	4.72e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CRABP1—esophageal cancer	3.31e-06	4.71e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	3.29e-06	4.69e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PTGS2—esophageal cancer	3.28e-06	4.67e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	3.27e-06	4.66e-05	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—TP53—esophageal cancer	3.27e-06	4.66e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—NOS3—esophageal cancer	3.27e-06	4.65e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—EP300—esophageal cancer	3.26e-06	4.64e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—ABCB1—esophageal cancer	3.22e-06	4.59e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—CREBBP—esophageal cancer	3.21e-06	4.57e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—MYC—esophageal cancer	3.19e-06	4.55e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—TPI1—esophageal cancer	3.17e-06	4.52e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GSTO1—esophageal cancer	3.17e-06	4.52e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GNG7—esophageal cancer	3.15e-06	4.48e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—NOS3—esophageal cancer	3.13e-06	4.46e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—EGFR—esophageal cancer	3.12e-06	4.45e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—MYC—esophageal cancer	3.12e-06	4.44e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—HMOX1—esophageal cancer	3.11e-06	4.43e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—EP300—esophageal cancer	3.07e-06	4.37e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—EGFR—esophageal cancer	3.05e-06	4.35e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ALDOB—esophageal cancer	3.04e-06	4.33e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—CREBBP—esophageal cancer	3.04e-06	4.32e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—NOS2—esophageal cancer	3.01e-06	4.29e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—EP300—esophageal cancer	3e-06	4.27e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PTGS2—esophageal cancer	2.99e-06	4.25e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—NOTCH1—esophageal cancer	2.99e-06	4.25e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—ABCB1—esophageal cancer	2.98e-06	4.25e-05	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—PIK3CA—esophageal cancer	2.97e-06	4.22e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ALDH2—esophageal cancer	2.95e-06	4.2e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GAPDH—esophageal cancer	2.93e-06	4.17e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	2.92e-06	4.16e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CRABP1—esophageal cancer	2.9e-06	4.13e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—CREBBP—esophageal cancer	2.89e-06	4.12e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—NOS3—esophageal cancer	2.87e-06	4.09e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PTGS2—esophageal cancer	2.86e-06	4.08e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	2.85e-06	4.06e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—MYC—esophageal cancer	2.84e-06	4.04e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	2.83e-06	4.02e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GSTT1—esophageal cancer	2.81e-06	4e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—EGFR—esophageal cancer	2.78e-06	3.95e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP2A6—esophageal cancer	2.77e-06	3.95e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.76e-06	3.94e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GNG7—esophageal cancer	2.76e-06	3.93e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—EP300—esophageal cancer	2.73e-06	3.88e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—NOS3—esophageal cancer	2.72e-06	3.87e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—PIK3CA—esophageal cancer	2.71e-06	3.86e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CREBBP—esophageal cancer	2.71e-06	3.85e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—PIK3CA—esophageal cancer	2.65e-06	3.77e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ENO1—esophageal cancer	2.63e-06	3.74e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PTGS1—esophageal cancer	2.63e-06	3.74e-05	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.63e-06	3.74e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PTGS2—esophageal cancer	2.63e-06	3.74e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PSME2—esophageal cancer	2.59e-06	3.69e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PSME1—esophageal cancer	2.59e-06	3.69e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—NOS3—esophageal cancer	2.59e-06	3.69e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ALDH2—esophageal cancer	2.59e-06	3.68e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	2.56e-06	3.65e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—CREBBP—esophageal cancer	2.52e-06	3.59e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—EP300—esophageal cancer	2.48e-06	3.54e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GSTT1—esophageal cancer	2.46e-06	3.5e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	2.44e-06	3.47e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP2A6—esophageal cancer	2.43e-06	3.46e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—NOS3—esophageal cancer	2.42e-06	3.45e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—PIK3CA—esophageal cancer	2.41e-06	3.43e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—EP300—esophageal cancer	2.38e-06	3.39e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PTGS2—esophageal cancer	2.37e-06	3.37e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ENO1—esophageal cancer	2.3e-06	3.28e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PTGS1—esophageal cancer	2.3e-06	3.28e-05	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.3e-06	3.28e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PIK3CA—esophageal cancer	2.27e-06	3.23e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PSME2—esophageal cancer	2.27e-06	3.23e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PSME1—esophageal cancer	2.27e-06	3.23e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—CREBBP—esophageal cancer	2.27e-06	3.23e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—ERBB2—esophageal cancer	2.27e-06	3.23e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.26e-06	3.22e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—NOS3—esophageal cancer	2.26e-06	3.21e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP1B1—esophageal cancer	2.24e-06	3.18e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PIK3CA—esophageal cancer	2.22e-06	3.16e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PTGS2—esophageal cancer	2.22e-06	3.16e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—EP300—esophageal cancer	2.18e-06	3.11e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—CREBBP—esophageal cancer	2.15e-06	3.07e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP19A1—esophageal cancer	2.1e-06	2.99e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—EP300—esophageal cancer	2.07e-06	2.94e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PTGS2—esophageal cancer	2.06e-06	2.94e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—NOS3—esophageal cancer	2.03e-06	2.89e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PIK3CA—esophageal cancer	2.02e-06	2.87e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CREBBP—esophageal cancer	1.99e-06	2.84e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—EP300—esophageal cancer	1.97e-06	2.81e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP1B1—esophageal cancer	1.96e-06	2.79e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CDKN1A—esophageal cancer	1.94e-06	2.76e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—NOS3—esophageal cancer	1.93e-06	2.75e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—HMOX1—esophageal cancer	1.92e-06	2.73e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.88e-06	2.68e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PTGS2—esophageal cancer	1.86e-06	2.64e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—EP300—esophageal cancer	1.84e-06	2.62e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP19A1—esophageal cancer	1.84e-06	2.62e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ABCB1—esophageal cancer	1.84e-06	2.62e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PIK3CA—esophageal cancer	1.84e-06	2.62e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—NOS3—esophageal cancer	1.79e-06	2.54e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PTGS2—esophageal cancer	1.76e-06	2.51e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PIK3CA—esophageal cancer	1.76e-06	2.51e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—EP300—esophageal cancer	1.72e-06	2.44e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—HMOX1—esophageal cancer	1.68e-06	2.39e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PTGS2—esophageal cancer	1.63e-06	2.33e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PIK3CA—esophageal cancer	1.62e-06	2.3e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MYC—esophageal cancer	1.61e-06	2.29e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—EGFR—esophageal cancer	1.57e-06	2.24e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—EP300—esophageal cancer	1.54e-06	2.2e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PIK3CA—esophageal cancer	1.53e-06	2.18e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—TP53—esophageal cancer	1.48e-06	2.11e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—EP300—esophageal cancer	1.47e-06	2.09e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PIK3CA—esophageal cancer	1.46e-06	2.08e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.39e-06	1.98e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PIK3CA—esophageal cancer	1.36e-06	1.94e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—EP300—esophageal cancer	1.36e-06	1.93e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PIK3CA—esophageal cancer	1.27e-06	1.81e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CREBBP—esophageal cancer	1.23e-06	1.75e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PIK3CA—esophageal cancer	1.14e-06	1.63e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—NOS3—esophageal cancer	1.1e-06	1.57e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PIK3CA—esophageal cancer	1.09e-06	1.55e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CREBBP—esophageal cancer	1.08e-06	1.54e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PTGS2—esophageal cancer	1.01e-06	1.44e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PIK3CA—esophageal cancer	1.01e-06	1.43e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—NOS3—esophageal cancer	9.66e-07	1.37e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PTGS2—esophageal cancer	8.83e-07	1.26e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—EP300—esophageal cancer	8.38e-07	1.19e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—EP300—esophageal cancer	7.35e-07	1.05e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PIK3CA—esophageal cancer	6.2e-07	8.83e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PIK3CA—esophageal cancer	5.43e-07	7.74e-06	CbGpPWpGaD
